Prashant Paroda of Allspring Global Investments believes the tariff impact on Indian generic pharma will be limited, as they are key to controlling US healthcare costs. He suggests the Indian market’s next trigger will be domestic, pinning hopes on a consumption revival during the Diwali festival season, especially in auto sales. Given India’s recent underperformance, he feels an earnings recovery could spur market gains.
